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Abstract 
Background: Smoking and chronic obstructive pulmonary disease (COPD) are risk 
factors for cardiovascular disease, and the pathogenesis may involve endothelial 
dysfunction. We tested the hypothesis that endothelium-derived epoxyeicosatrienoic 
acid (EET)-mediated endothelial function is impaired in patients with COPD, and a 
novel sEH inhibitor GSK2256294 attenuates EET-mediated endothelial dysfunction 
in human resistance vessels both in vitro and in vivo.
 
Methods: Endogenous and stimulated endothelial release of EETs was assessed in 
12 COPD patients, 11 overweight smokers, and 2 matched control groups, using 
forearm plethysmography with intra-arterial infusions of fluconazole, bradykinin, and 
the combination. The effects of GSK2256294 on EET-mediated vasodilatation in 
human resistance arteries were assessed in vitro and in vivo in a Phase 1 clinical 
trial in healthy overweight smokers.  
Results: Compared to controls, there was reduced vasodilatation to bradykinin 
(p=0.005), blunted effect of fluconazole on bradykinin-induced vasodilatation 
(p=0.03), and a trend towards reduced basal EET/DHETs ratio in COPD patients 
(p=0.08). A similar pattern was observed in overweight smokers. In vitro, 10 µM 
GSK2256294 increased 11,12-EET-mediated vasodilatation compared to vehicle 
(90±4.2% vs. 72.6±6.2% maximal dilatation), and shifted the bradykinin EC50 (-
8.33±0.172 vs. -8.10±0.118 logM; p=0.001 for EC50). In vivo, 18 mg GSK2256294 
improved the maximum bradykinin response from 338±46% pre-dose to 566±110% 
post single dose (p=0.02), and to 503±123% post chronic dose (p=0.003). 
Conclusion: GSK2256294 attenuates smoking related EET-mediated endothelial 
dysfunction, suggesting potential therapeutic benefits in patients with COPD.  
Trial Registration: ClinicalTrials.gov NCT01762774 
 
Key words: soluble epoxide hydrolase inhibitor, endothelial function, smokers, clinical 
trial, EETs, COPD  
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Introduction 
Chronic obstructive pulmonary disease (COPD) is the third leading cause of 
death worldwide, and a risk predictor for atherosclerosis.1,2,3 Several 
pathophysiological processes may contribute to disease progression, and increased 
cardiovascular risk in COPD, including systemic effects of smoking, chronic 
inflammation,4 and endothelial dysfunction.5 Patients with COPD are also more likely 
to suffer from other cardiovascular co-morbidities, including central abdominal 
obesity, and the metabolic syndrome, particularly in earlier stages of COPD.6–8 
Endothelium-derived hyperpolarising factors (EDHF), particularly epoxyeicosatrienoic 
acids (EETs) are involved in the modulation of vascular tone,9 attenuation of 
inflammation,10 and activation of fibrinolysis by augmenting tissue plasminogen 
activator (tPA) expression.11  
EETs are synthesised by cytochrome P450 (CYP) enzymes, and metabolised 
to their less biologically active diols by soluble epoxide hydrolase (sEH) enzymes.12 
Smoking has a synergistic effect with CYP450 and sEH polymorphisms,13 resulting in 
enhanced sEH activity, reduced plasma EETs, and increasing overall risk of 
myocardial infarction.14 Plasma EETs levels are reduced in patients with coronary 
artery disease who are obese, or who smoke.15 EETs are also produced in lung 
epithelial cells, and they may become dysfunctional in COPD.12 In vivo, smokers 
exhibit reduced endothelial responses to bradykinin,5 and this may be associated 
with impaired EDHF-mediated vasodilatation.16,17 However, the functional role of 
EETs has not yet been characterised in humans. 
Up-regulation of EETs by sEH inhibition in animals improves the metabolic 
syndrome,18 lung function, and attenuates smoking-related inflammation and 
emphysema.19 GSK2256294 is a novel potent sEH inhibitor in Phase 1 clinical 
development, and may have the potential to impact upon systemic and pulmonary 
endothelial function. As this was a Phase 1 clinical trial, mainly focussed on safety, 
and tolerability in the healthy, we used a cohort of overweight smokers as a 
representative for patients with early stage COPD. 
We hypothesised that EETs synthesis is reduced in patients with COPD and 
otherwise healthy overweight smokers, and that sEH inhibition would up-regulate 
EETs and endothelial dysfunction. We completed a physiological study, in which we 
assessed EETs-mediated basal tone, and the EETs component of bradykinin 
stimulated vasodilatation in patients with COPD, and in overweight smokers, in order 
to maximise the impact of cardiovascular risk factors in otherwise healthy subjects. 
Subsequently, we examined the effects of a novel sEH inhibitor GSK2256294 in 
human resistance arteries in vitro, and in vivo in a Phase 1 clinical trial with an 
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experimental medicine arm to provide early proof-of-mechanism for target 
engagement in overweight smokers. The study design, safety and pharmacokinetic 
data from the Phase 1 trial were reported separately,20 and we only report the effects 
of sEH inhibition on endothelial function in this manuscript. 
 
Materials and Methods 
All study procedures were conducted in accordance with the Declaration of 
Helsinki, approved by appropriate institutional review boards, and received 
favourable opinions from local ethics committees (13/EE/0032, 12/LO/1832), and the 
Medicines and Healthcare products Regulation Agency. Analysis and Statistical 
methods are described in the supplementary material. All subjects were recruited 
following written consent.  
We used forearm venous occlusion plethysmography21 to assess vascular 
function in vivo with intra-arterial infusion of challenge agents via a 27-gauge needle 
(Coopers Needleworks, Birmingham, UK) inserted into the brachial artery. Venous 
plasma concentrations of EET/DHETs were assessed as a representative of sEH 
activity at baseline, and during the forearm blood flow studies. Oscillometric blood 
pressures were monitored in the non-infused arm. Detailed methods and statistical 
analyses are in the supplementary material. 
Study 1 
Twelve male COPD patients (FEV1/FVC < 0.7 and FEV1 < 80% post-
bronchodilator), and 12 healthy gender matched controls (matched controls 1) 
underwent a single forearm blood flow study to assess EETs mediated vasodilatation 
(UKCRN Portfolio ID: 14339). Patients taking concomitant medications which 
interfere with CYP450 or cyclo-oxygenase enzymes were asked to stop for at least 4 
days prior to the forearm blood flow. Overall endothelium-dependent function was 
assessed by infusing bradykinin (100, 300 and 1000 pmol/min, Bachem Distribution 
Services GmbH, Germany), and stimulated EETs release was assessed by co-
infusing bradykinin with 0.4 µmol/min fluconazole; a cytochrome P450 inhibitor which 
inhibits EETs synthesis (Pfizer Ltd, Kent, UK).9 (Supplementary material figure 1). 
Endothelium-independent responses were assessed using 12, and 38 nmol/min (3, 
and 10 µg/min) sodium nitroprusside (SNP) (Nitroprussiat FIDES, Madrid, Spain). 
Study 2 
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Twelve overweight smokers (≥10 cigarettes/day, and >5 pack-year history, 
weight >60kg and BMI 28-35kg/m2), and equal numbers of healthy gender and age-
matched non-smoker controls (matched controls 2) underwent the same forearm 
blood flow protocol as subjects in Study 1.  
Study 3 
We first assessed the effects of sEH inhibition, in vitro, by application of 
GSK2256294 to human resistance arteries treated with L-nitroarginine methyl ester 
(LNAME), and indomethacin (detailed methods in supplementary material), and in 
vivo, using forearm blood flow pre-dose, after a single dose (acute effects), and after 
14 days (chronic effects) of oral GSK2256294. Responses to bradykinin (300, 600 
and 1000 pmol/min) were assessed in the presence of 8 µmol/min NG-monomethyl-L-
arginine (LNMMA; Bachem) and 6 mmol (1 g) intravenous aspirin (Aspergic Sanofi-
Aventis, France) to inhibit NO and PGI2 syntheses in order to maximise EDHF and 
EETs (Supplementary material figure 2). Venous concentrations of t-PA and 
plasminogen activator inhibitor-1 (PAI-1) were measured before and after each dose 
of bradykinin.22 Challenge agent doses were chosen based on previous studies.5,5 
To assess the effects of GSK2256294 in vivo, we studied healthy overweight 
smokers (no concomitant medications) as a paradigm for a COPD population in a 
Phase 1 clinical trial to provide early proof of mechanism (ClinicalTrials.gov 
NCT01762774). Thirty male overweight smokers, were allocated in a 2:1 ratio 
between GSK2256294 (6 mg or 18 mg) and placebo for 14 days repeat dose. 
GSK2256294 doses were chosen based on enzyme inhibition and pharmacokinetic 
data from the single dosing cohorts.20  
Results 
Study 1 
Subject demographics are presented in Table 1. The average FEV1 was 
53±13% predicted, and FEV1/FVC ratio was 0.5±0.1 in the COPD subjects. There 
was a trend towards higher plasma concentration of basal EET/DHETs ratio in 
matched controls 1 compared to COPD patients (0.54±0.12 vs. 0.45±0.14; p=0.08) 
(Figure 1). 
There was a dose-dependent increase in forearm blood flow ratio following 
bradykinin in both groups (p<0.0001). Bradykinin response was significantly higher in 
matched controls 1 than patients with COPD (maximal dilatation 1314±191% vs. 
552±103%; p=0.005) (Figure 2A). In the presence of fluconazole, maximum 
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dilatation to bradykinin was reduced in matched controls 1 (406±64%; p<0.0001), but 
not in patients with COPD (447±124%; p=0.32), showing a significant between group 
difference in inhibition (p=0.03). There was no difference in SNP response between 
groups (data not shown). Blood pressure remained constant throughout the studies. 
Although not significant, plasma concentrations of EET/DHETs ratio in 
response to bradykinin was higher in matched controls 1 compared to patients with 
COPD (maximum 8.6±3.4 vs. 6.8±1.1; p=0.83). In the presence of fluconazole, 
although not significant, total EET/DHETs were slightly less in matched controls 1 
(maximum 4.7±0.4; p=0.27), but not in patients with COPD (5.2±0.9; p=0.70) (Figure 
3A).  
 
Study 2 
Although not significant, basal EET/DHETs ratio was higher in matched 
controls 2 compared to overweight smokers (0.46±0.06 vs. 0.39±0.04; p=0.33) 
(Figure 1). 
Bradykinin response was higher in matched controls 2 than overweight 
smokers (maximal dilatation: 930±81% vs. 575±112%; p=0.02) (Figure 2B). In the 
presence of fluconazole, maximum dilatation to bradykinin was reduced in matched 
controls 2 (400±49%; p<0.0001), but not in overweight smokers (437±57%; p=0.16), 
resulting in a significant between group difference (p=0.002). There was no 
difference in SNP response between groups (data not shown). Blood pressure 
remained constant throughout the studies. There was no difference in the bradykinin 
response between COPD and overweight smokers (p=0.72). 
Although not significant, the increase in EET/DHETs ratio in response to 
bradykinin was higher in healthy matched controls 2 compared with overweight 
smokers (maximum 10.31±4.43 vs. 5.66±0.46; p=0.80). In the presence of 
fluconazole, EET/DHETs were reduced in matched controls 2 but slightly increased 
in overweight smokers (maximum 5.02±0.38 vs. 8.19±2.18; p=0.003) (Figure 3B).  
 
Study 3 
In LNAME and indomethacin treated resistance vessels, GSK2256294 10 µM 
increased 11,12-EET-mediated vasodilatation compared to vehicle (n=6 in each 
group, 90±4% vs. 73±6% maximal dilatation; Figure 4A), and shifted the bradykinin 
EC50 (n=6, -8.33±0.17 vs. -8.10±0.12 logM; p=0.001; Figure 4B). However, 
vasodilatation to 8,9-EET was unaltered (82±16% vs. 72±19%, maximal dilatation), 
suggesting that the effects were regio-isomer specific. The vasodilatation to 
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papaverine (100 µM), a test of direct smooth muscle vasodilatation, was unchanged 
in GSK2256294. 
In vivo, 28 subjects, including the 11 who took part in the physiological study, 
completed forearm blood flow studies at pre-dosing, after a single dose, and after 14 
days repeat dosing with placebo (n=6) or GSK2256294 6 mg or 18 mg (n=11 in each 
group) (Table 1). There was a trend to increased bradykinin response after single 
and repeat dosing in the active treatment groups. In subjects who received 6 mg, 
response to bradykinin increased by 23±17% on day 1 and by 22±22% on day 14. In 
those who received 18 mg, bradykinin response increased by 14±17% on day 1, and 
12±14% on day 14. Responses to SNP did not change. 
In a post-hoc analysis of forearm blood flow ratio, there was an 
improvement in bradykinin-induced responses following dosing with the active 
drug compared to placebo (p=0.007), with the greatest effect in the active 
drug 18 mg group. In the 18 mg active drug group, the maximum bradykinin 
response improved from 338±46% pre-dose to 566±110% post single dose 
(p=0.02), and to 503±123% post chronic dose (p=0.003). (Figure 5). 
LNMMA and aspirin inhibited basal flow equally on all three days in the three 
treatment arms (Supplementary material Table 1). Blood pressure remained stable, 
and there were no changes to t-PA in response to BK, or in PAI-1 release (data not 
shown). 
 
Discussion 
The findings from these studies suggest that COPD and smoking are 
associated with impaired overall endothelial function, and reduced stimulated 
vascular EETs production. Proof-of-mechanism data demonstrates that sEH 
inhibition with GSK2256294 results in improvements in vascular function both in vitro 
and in vivo.  
We elected to study patients with COPD and overweight smokers as the 
mechanisms behind COPD, smoking and cardiovascular disease remains poorly 
understood. Both smokers and patients with COPD exhibit low-grade systemic 
inflammation,1 which plays a key role in endothelial activation, resulting in endothelial 
dysfunction, and the initiation of atherosclerosis.23 It has been demonstrated that 
patients with COPD,5 smokers,24 and ex-smokers25 exhibit a similar degree of 
endothelial dysfunction, suggesting that smoking may be the key contributing factor. 
Cardiovascular risk factors are more likely to cluster in obesity, manifesting as a 
syndrome of increased adipocytes, hyperglycaemia, and dyslipidaemia, with 
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underlying low-grade inflammation. In normotensive overweight subjects with the 
metabolic syndrome, acetylcholine-, rather than bradykinin-induced vasodilatation is 
reduced, possibly suggesting a lesser degree of endothelial dysfunction.9 However, 
the extent to which EETs contributed to this endothelial dysfunction remained 
unclear, and our study was the first to interrogate this further, and forearm blood flow 
data suggest that EETs production is similarly impaired in patients with COPD and 
overweight smokers, supported by plasma quantification of EETs/DHETs as a 
representative of sEH activity. 
We observed a trend towards reduced baseline EET/DHETs in patients with 
COPD and overweight smokers, and when comparing the two matched control 
groups, baseline EET/DHETs ratio are slightly less in the younger matched controls 
for overweight smokers (matched control 2), than those for COPD (matched control 
1). However, human plasma EETs, and DHETs are notoriously difficult to quantify, 
due to their instability, thus, definitive conclusions cannot be drawn from these 
insignificant results, but can only be taken in context of our forearm blood flow data, 
and previous published data. In animals, obesity is associated with reduced hepatic 
expression of EETs-producing CYP2C enzymes.26 In mesenteric arteries of obese 
Zucker rats, there is reduced CYP2C and CYP2J enzymes, with enhanced activity of 
sEH enzymes.27 Increased sEH activity may represent more advanced inflammation, 
as in coronary artery disease, those who are obese or who smoke exhibit the lowest 
EET/DHETs ratio.15 sEH activity is associated with forearm blood flow, as subjects 
with Lys55Arg polymorphism in the sEH encoding gene (EPHX2) exhibit higher sEH 
activity, and reduced vasodilator responses to bradykinin.28 Smoking can also 
significantly upregulate EPHX229, and this is associated with increased coronary 
artery calcification in man.13 
The reduced EETs synthesis and endothelial dysfunction observed in patients 
with COPD and overweight smokers, may be a result of chronic low grade 
inflammation secondary to smoking.30 In animals, dimethylsulfoxide-soluble smoke 
particles can up-regulate endothelium-derived vasoconstrictors via the nuclear factor 
kappa-light-chain-enhancer of activated B cells (NFκB);31 a pivotal protein controlling 
the transcription of genes relevant to the pathophysiology of the blood vessel wall, 
including adhesion molecules and cytokines.32 EETs exert their anti-inflammatory 
effects by inhibiting the activation of NFκB.32 Inflammatory states are associated with 
down-regulation of hepatic and extrahepatic CYP450 enzymes, resulting in a vicious 
cycle of reduced EETs production and an ineffective EETs-mediated anti-
inflammatory effect both locally and systemically.33  
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GSK2256294 is a potent sEH inhibitor, which exerts high levels of sEH 
enzyme inhibition both in vitro,19 and in vivo.20 In human left internal mammary 
arteries, 11,12-EETs are the most potent regio-isomer,34 and we confirmed that both 
11,12-EETs and bradykinin mediated vasodilatation were enhanced in the presence 
of GSK2256294 in human resistance arteries. In animal models of cigarette smoking 
and obesity, sEH inhibition improves lung,35 and endothelial function,36 and 
attenuates pulmonary inflammation as reflected by reduced inflammatory cells 
including neutrophils, and macrophages.19 In human bronchial cells, treatment with 
exogenous EETs protects against cigarette smoke extract–induced injury.37 
Consistent with in vitro results, both acute and chronic sEH inhibition for up to two 
weeks improve responses to bradykinin.  
No changes were observed in t-PA release following sEH inhibition. t-PA is a 
fibrinolytic serine protease that is released from the endothelium, and regulates 
degradation of intravascular fibrin. Impaired t-PA release can be associated with 
coronary atherosclerosis, and cigarette smoking.25 Treatment of human endothelial 
cells with exogenous EETs, particularly 11,12-EETs, can increase t-PA protein 
expression in a dose and time-dependent manner, possibly due to activation of a G-
protein, whilst not affecting plasminogen activator inhibitor type 1 (PAI-1), the 
endogenous inhibitor of t-PA.11 t-PA release may also be dependent on the agonist, 
and in this group of overweight smokers, substance P may elicit a greater 
response.24 
Some limitations of this study warrant consideration. As the main focus of the 
Phase 1 clinical trial was on safety, tolerability, and pharmacokinetics of 
GSK2256294 in healthy volunteers, we were not able to test this novel drug in COPD 
patients. In addition, the lack of non-smoking controls in the Phase 1 clinical trial 
means that the magnitudes of the effects of both doses of GSK2256294 were 
relatively small, and similar to the variance in bradykinin responses in the placebo 
group. Therefore, Phase 2 studies in larger patient groups are required to draw 
definitive conclusions. 
Some evidence also suggests that in NO deficient conditions, EETs may be 
upregulated.9 Thus, by creating an NO deficient milieu during the forearm blood flow 
study with LNMMA, we may have masked any further up-regulation of EETs by sEH 
inhibition. Larger clinical trials in patients with COPD, without concomitant inhibition 
of nitric oxide synthase, would be required to further understand the clinical impact of 
sEH inhibition. This must also be approached with caution for the potential of EETs 
to stimulate angiogenesis, and possibly modulate cancer genesis and metastases,38 
though, interestingly, dual action cyclo-oxygenase and sEH inhibition may in fact 
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suppress cancer.39 We found no changes in serum vascular endothelial growth factor 
the active drug group with this dosing regime after 14 days.20  
 
Conclusions 
Patients with COPD and overweight smokers have impaired endothelial 
function, and dysregulated EETs signalling. sEH inhibition can augment bradykinin-
induced vasodilatation in human resistance vessels both in vitro and in vivo, 
suggesting that sEH inhibition may be a novel therapeutic target to ameliorate 
cardiovascular risk in patients with smoking related endothelial dysfunction.  
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Tables 
Table 1. Demographics for all study subjects 
Subject 
Demographics 
(mean ± SD) 
COPD Group Overweight smoker Group Phase 1 Clinical  (Overweight smokers) 
COPD 
(n=12)  
Control 
(n=12) 
Significanc
e 
Overweight 
Smokers 
(n=11) 
Control 
(n=12) 
Significanc
e 
6 mg  18 mg  Placebo  Significan
ce (n=11) (n=11) (n=6) 
Age (Years) 63 ± 6 64 ± 7 p=0.70 48 ± 8 49 ± 10 p=0.47 43 ± 10 42 ± 9 41 ± 8 p=0.92 
BMI (kg/m2) 27 ± 3 26 ± 3 p=0.33 30 ± 3 25 ± 2 p<0.0001  31 ± 2 31 ± 2 31 ± 3 p=0.72 
Height (m) 1.75 ± 0.3 1.77 ± 0.1 p=0.33 1.82 ± 0.1 1.80 ± 0.1 p=0.73 
1.83 ± 
0.06 
1.78 ± 
0.04 
1.76 ± 
0.09 p=0.11 
Weight (kg) 84 ± 12 82 ± 11 p=0.77 103 ± 13 80 ± 7 p<0.0001  103 ± 10 98 ± 10 95 ± 9 p=0.25 
Supine SBP 
(mmHg) 130 ± 17 133 ± 7 p=0.52 130 ± 14 124 ± 14 p=0.26 128 ± 16 141 ± 13 130 ± 13 p=0.09 
Supine DBP 
(mmHg) 80 ± 3 82 ± 5 p=0.77 82 ± 5 78 ± 8 p=0.34 79 ± 7 82 ± 8 76 ± 5 p=0.26 
Pack Years 39 ± 17 0 N/A 21 ± 11 0 N/A 20 ± 10 17 ± 9 16 ± 6 p=0.58 
 
Table 1: Subject demographics for the physiological study and Phase 1 clinical trial. There were no significant differences in the demographics 
between overweight smokers and healthy matched controls in the physiological study, and no differences between placebo, 6 mg, and 18 mg 
active drug.  For the physiological study, p value was calculated using a student’s t-test for COPD vs matched controls, and for the Phase 1 
clinical trial, p value was calculated using one-way ANOVA comparison between three treatment groups 
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Abbreviations 
COPD, chronic obstructive pulmonary disease 
CYP, cytochrome P450 
DHET, dihydroxyepoxyeicosatrienoic acid 
EDHF, endothelium-derived hyperpolarising factor 
EET, epoxyeicosatrienoic acid 
FBF, forearm blood flow 
NFκB, nuclear factor kappa-light-chain-enhancer of activated B cells 
NO, nitric oxide 
PAI-1, plasminogen activator inhibitor type 1 
sEH, soluble epoxide hydrolase 
tPA, tissue plasminogen activator 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
	  
Online supplements are not copyedited prior to posting and the author(s) take full responsibility for the accuracy of all data.  
e-Appendix 1. Materials and Methods 
Plasma quantification of EETs/DHETs 
Venous blood samples were collected from the same arm as the arterial infusion at baseline, and before 
and after each dose of bradykinin. Approximately 2 mL of blood was collected in lithium heparin tubes, 
immediately centrifuged at 4°C at 4600 rpm for 5 minutes (Hettich Zentrifugen Rotanta 460R, Germany), 
then rapidly frozen with liquid nitrogen or dry ice, and stored in -80°C. Thawed samples were prepared by 
methanol crash method,1 and EETs and DHETs were measured by high performance liquid 
chromatography and tandem mass spectrometry using an Aquity Ultra Performance Liquid Chromatogram 
(Waters Ltd., Manchester) coupled with an AB Sciex 5500 mass spectrometer (Ab Sciex, Warrington).2 
Effect of GSK2256294 in vitro 
For in vitro assessment of human microvascular function, tissue samples were obtained from 
otherwise discarded visceral fat (omentum and mesentery) of patients undergoing surgeries, including 
colectomy, renal transplantation, liver resection, and breast reconstruction. Comorbid conditions included 
hypertension, cancer, and inflammatory bowel disease, and diverticulitis, but samples were taken from 
unaffected areas wherever possible. Medication history was unavailable, but tissue was washed in buffer 
for approximately one hour prior to study, in order to minimise the effects of any concomitant drugs. 
Human resistance arteries (100–200 µm) were isolated from the discarded surgical tissue, and 
cannulated with two glass micropipettes for videomicroscopic measurements of diameter.3 Vessels were 
pressurised to an intramural pressure of 60 mmHg under no-flow conditions and equilibrated at 37°C in 
Krebs-PSS gassed with 21% O2-5% CO2. Arteries were pre-constricted with endothelin-1 (ET-1; 0.3 nM) 
to 50%, and the bradykinin response was examined before and after 30min of L-nitroarginine methyl 
ester (L-NAME; 100 µM) and indomethacin (10 µM). Dose response curves to bradykinin (BK,10-10 to 10-4 
M), endothelin-1 (ET-1, 30 to 900 pM), 8,9-EET (10-10 to 10-6 M) and 11,12-EET (10-10 to 10-6 M) were 
generated in the presence or absence of GSK2256294. Responses to papaverine (10-4 M) were determined 
at the end. Vascular responses were expressed as percent maximal relaxation to ET-1 preconstriction; 
100% represents the passive baseline diameter. 
Statistical Analysis 
FBF data were analysed using LabChart 8 (ADInstruments, Oxford, United Kingdom), and statistical 
analysis was performed in R version 3.2.2 and GraphPad Prism (Version 6, GraphPad Software, California, 
USA). To test the hypothesis that EETs modulate basal tone, baseline FBF change in response to inhibitors 
were analysed as change in the infused arm only to eliminate possible systemic effects, and compared 
using paired Student’s t-test or one-way analysis of variance (ANOVA). Agonist responses were analysed 
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as forearm blood flow ratio (infused/non-infused arm), adjusted for baseline, and log-transformed. To 
assess EETs mediated agonist induced response in COPD and healthy subjects, log-transformed ratio 
increase were compared using repeated measures ANOVA with a nested three-way interaction term for 
multiple comparisons between the disease groups (COPD vs. healthy), and within subject comparisons 
between three bradykinin doses (100, 300 and 1000 pmol/min), and in the presence of fluconazole. 
Detailed post-hoc comparisons were made with Tukey adjustment.  
Plasma concentrations of each regio-isomer of the eicosanoids were corrected for baseline 
(concentration/baseline), and expressed as EET/DHET ratio as a surrogate of sEH activity, and presented 
as sum of EET/DHETs ratio.4 Sum of corrected ratios were log transformed, and analysed by repeated 
measures ANOVA with a nested three-way interaction term for multiple comparisons between groups 
(COPD vs. healthy), and within subject comparisons in the response to bradykinin, and bradykinin plus 
fluconazole. 
To assess the effects of GSK2256294, in vitro studies of arteriolar reactivity was analysed with a 
one-way repeated measures ANOVA for dose and condition, with a Tukey post-hoc correction. When 
vessels from the same patient were used for identical protocols, values were averaged for statistical 
analysis ("n's" represent the number of subjects, not vessels). ED50’s were compared by t-test in the 
presence or absence of inhibitor. In vivo, changes in FBF in the infused arm in response to bradykinin in 
acute and chronic dosing was compared to pre-dosing. All three treatment arms (placebo, 6 mg, and 18 
mg) were fitted in the same model with three agonist doses (change from baseline flow in response to 
300, 600 and 1000 pmol/min bradykinin) for each visit (Pre-dose, Day 1, and Day 14) via a three-way 
interaction term. A post-hoc analysis of the FBF ratio (infused/non-infused) was performed to adjust for 
any changes in the non-infused arm. Log-transformed baseline adjusted ratios were compared using 
repeated measures ANOVA with a nested three-way interaction term for multiple comparisons between 
the three treatment arms (placebo, 6 mg and 18 mg active drug), and within subject comparisons 
between bradykinin doses and treatment days, with Tukey adjustment. A similar analysis was performed 
for SNP responses. Results are expressed as mean±SEM unless otherwise indicated.  
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e-Table 1. Phase 1 clinical trial: percentage inhibition of basal flow in the infused arm by 
LNMMA plus aspirin in the placebo, 6mg and 18mg groups.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
e-Table 1. Percentage change in baseline forearm blood flow in the infused arm following LNMMA plus 
aspirin at pre-dose, Day 1, and Day 14 post-dose. Overall, LNMMA and aspirin had a significant inhibitory 
effect (p<0.0001), but this effect is variable, although no different between treatment days. There were 
no differences in inhibition between placebo, 6 mg or 18 mg (p=0.33). Abbreviations: LNMMA; NG-
monomethyl-L-arginine, SEM; standard error of the mean.  
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Percentage inhibition of baseline flow in the infused arm by 
LNMMA and aspirin (Mean ± SEM) 
Placebo 
Inhibitor 
effect 6mg 
Inhibitor 
effect 18mg 
Inhibitor 
effect 
Pre-dosing 
-
35.46±5.65 
p=0.01 
-
31.21±5.35 
p=0.003 
-
30.53±6.23 
p=0.004 
Day 1 post-
dosing 
-
22.22±4.56 
p=0.24 
-
19.14±6.72 
p=0.07 
-
24.72±4.79 
p=0.0008 
Day 14 post-
dosing 17.67±9.88 p=0.59 
-
21.40±9.33 
p=0.03 
-
28.18±4.91 p=0.02 
Difference 
between pre-
dosing and Day 1 p=0.98 
 
p=1.00 
 
p=0.67 
 
Difference 
between pre-
dosing and Day 
14 p=0.99 
p=0.99 p=0.44 
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e-Figure 1. 
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